▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #5 by analyst upside · 2026-11-13
KPTI
Karyopharm Therapeutics Inc.
Healthcare · Market Cap $0M · P/E 0x
ANALYST PRICE TARGET
+42045.6%
implied upside to consensus target
Current Price $0.02
Consensus Target $7.33
Bull Target $11.0
Bear Target $3.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
1
Sell
0
52-Week Low $0.01
52-Week High $10.99
YTD Return -99.6%
FUNDAMENTALS
Market Cap $0M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-9.83
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $147M
Profit Margin -153.3%
52-WEEK RANGE
52-Week Low $0.01
52-Week High $10.99
Current Price $0.02
Bear Target $3.0
Bull Target $11.0
● Now $0.02 ● Target $7.33
TRADING DATA
Avg Volume 8.6M
YTD Return -99.6%
Analyst Count 3
Consensus Buy
Upside to Target +42045.6%
Last Updated 2026-11-13

ANALYST SUMMARY

Karyopharm Therapeutics Inc. (KPTI) is currently trading at $0.02 with a Wall Street consensus price target of $7.33, implying potential upside of 42045.6% over the next 12 months. 3 analysts currently cover KPTI, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $3.0.

KPTI operates in the Healthcare sector with a market capitalisation of $0M. The stock is down 99.6% year-to-date and is currently trading near the lower end of its 52-week range of $0.01 – $10.99.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KPTI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Rodman & Renshaw ↓ Downgrade
Buy → Neutral 2026-11-02 29% win rate (7 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-07-31 14% win rate (7 calls)
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-07-31 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-06 31% win rate (48 calls)
Piper Sandler reit
Overweight → Overweight 2026-04-27 14% win rate (7 calls)
Piper Sandler reit
Overweight → Overweight 2026-03-30 14% win rate (7 calls)
Baird - Reiterated
Outperform → Outperform 2026-03-25 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-25 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →